Loading...
DOCUMENTS
21
NOTICES
32
MOTS CLES
HIV
Clinical trial
Colorectal cancer
Inflammatory bowel diseases
Colon
Colectomy
T1118 translocation
Cost effectiveness
Over 80s
Gene expression
Kidney diseases
Microbiota
Gene methylation
Alkylating agents
Survival
Colorectal cancer Colibactin and lipids
Immunosuppressant
Eligibility
IL12
Patients experience
Crohn's disease
Small molecules
Bacteria
Disease progression
Dysbiosis
Cancer
Neoadjuvant chemotherapy
Venous thromboembolism
Anti-TNF agents
Resistance
Stricture
Résistance
MORTALITY
Safety
Biologics
Maintenance therapy
Effectiveness
IL23
Biomarker
Upper gastrointestinal tract
Genes
COLON-CANCER
Screening
Bactéries
Consensus
Immune cells
Primary sclerosing cholangitis
MARKER
Methylation
Drug
Tuberculosis
Epigenetics
DNA METHYLATION
DNA methylation
Contraindication
Ustekinumab
Inclusion
Tailored therapy
Monitoring
Anti-TNF
Intestinal crypts
Dysbiose
Fecal microbiota
PCR
Cell adhesion
Inflammatory bowel disease
Parvimonas micra
Endoscopic treatment
Helicobacter pylori
Clinical guidelines
Colonic epithelial primary cells
Disease Progression
Surgery
Heart disease risk factors
Patient-reported outcome
Acceptability
Rituximab plus chlorambucil
Inhibitor
Algorithm
Epigénétiques
Thérapie ciblée
Crohn’s disease
RISK
Inflammatory Bowel Diseases
Original Article Clinical
IBD
MALT
Rituximab
18 FDG-PET/CT
Gènes
Ulcerative colitis
CARCINOGENESIS
Méthylation
Colon cancer
Therapeutics
MICROBIOTA
Disability
Microbiote
Vedolizumab
Eradication
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|